ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma
Cancer
Leukemia

Non-Hodgkin Lymphoma trials near Montréal, QC, CAN:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Montreal, Quebec, Canada and 16 other locations

immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

Phase 1

Iksuda Therapeutics

Montréal, Quebec, Canada and 12 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Montreal, Quebec, Canada and 58 other locations

with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma...

Active, not recruiting
B-cell Non-Hodgkin Lymphoma
Drug: Polatuzumab vedotin
Drug: Tocilizumab

Phase 1, Phase 2

Roche
Roche

Montreal, Quebec, Canada and 28 other locations

participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, transformed folli...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tocilizumab
Drug: Gemcitabine

Phase 3

Roche
Roche

Montreal, Quebec, Canada and 51 other locations

alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be admin...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Glofitamab
Drug: Obinutuzumab

Phase 1, Phase 2

Roche
Roche

Montreal, Quebec, Canada and 38 other locations

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma...

Active, not recruiting
Non-hodgkin Lymphoma
Drug: Epcoritamab

Phase 1

Genmab
Genmab

Montreal, Quebec, Canada and 40 other locations

This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized ...

Active, not recruiting
Lymphoma, B-Cell
Hodgkin Disease
Biological: Favezelimab
Biological: pembrolizumab

Phase 1, Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Montreal, Quebec, Canada and 24 other locations

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...

Active, not recruiting
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Marginal Zone Lymphoma
Drug: Zanubrutinib
Drug: PRT2527

Phase 1

Prelude Therapeutics

Montreal, Quebec, Canada and 23 other locations

usual treatment lower the chance of primary central nervous system lymphoma growing or spreading?This study is being done to find out if thi...

Enrolling
Non-hodgkin Lymphoma
Drug: Rituximab (where available)
Drug: Ibrutinib

Phase 2

Canadian Cancer Trials Group

Montreal, Quebec, Canada and 6 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems